Alpelisib(Piqray)

Alpelisib is an oral phosphatidylinositol-3-kinase (PI3K) inhibitor. Its mechanism of action is to block the activity of PI3K enzymes, inhibit the proliferation and spread of tumor cells, and simultaneously induce the apoptosis of breast cancer cells.

50mg*28tablets
150mg*28tablets

WhatsApp

To ensure medication safety, consult customer service for free before purchasing. Returns/exchanges are not accepted except for quality issues.

Authentic

Guarantee

Fast Delivery

Privacy

Alpelisib Purchase Guide

Alpelisib: Number of Boxes per Treatment Cycle, Cost and Contraindications

Alpelisib is a targeted therapy directed against PIK3CA mutations, developed by Novartis Pharmaceuticals of Switzerland. This article provides a detai···【Read More】
Update: 02 Mar,2026Source: Haiou HealthViews: 71
Purchase Channels and Dosing Guidelines for Alpelisib

Alpelisib is a targeted therapy for specific types of breast cancer. The drug is not yet approved in mainland China and is not covered by medical insu···【Read More】
Update: 02 Mar,2026Source: Haiou HealthViews: 72